Mycn Conditional Knockout mouse — liver specific context

Encoding N-Myc, Mycn is the mouse ortholog of human MYCN and produces a basic helix-loop-helix leucine zipper factor that heterodimerizes with Max, occupies E-box elements, and drives ribosome biogenesis and cell cycle programs in neural crest, neuroblast, and cerebellar progenitors; like c-Myc it carries the Thr58 and Ser62 phosphodegron read by Fbxw7, but Aurora kinase A binding stabilizes the protein against that pathway, which is the mechanistic basis for Aurora A inhibitor strategies in MYCN-amplified disease. Genomic amplification defines high-risk neuroblastoma and also occurs in medulloblastoma and neuroendocrine prostate cancer. Homozygous nulls die in mid-gestation with neural, cardiac, and lung defects, so conditional deletion is required for progenitor studies, whereas lineage-restricted overexpression modeled on tyrosine hydroxylase promoter-driven designs remains the standard tumor-initiating allele, and a Thr58Ala knockin isolates degron control from expression level. Myc can substitute at the endogenous locus, so paralog dosage and driver specificity govern the phenotype.

A floxed Mycn allele paired with Cre gives spatial control that whole body knockouts cannot offer. People use it to separate developmental roles from adult homeostasis, to model somatic mutations, and to match disease that begins in one organ. For liver work, plan Cre specificity, reporter crosses, and baseline phenotyping before you scale.